Our production facility in Leiden
Our new production centre in Leiden will bring CAR-T cell therapy closer to cancer patients in Europe.
Bristol Myers Squibb chose the Leiden Bio Science Park as the European location for a new CAR-T cell therapy facility. With this new facility, we are investing in the expansion of our global network to bring cell therapy closer to patients in Europe.
This production centre is our first European site where we plant our BMS flag and will be our fifth facility worldwide working on the manufacturing of cell therapy. The facility will be equipped with the latest technology and manufacturing equipment. It took approximately three years, starting autumn 2021, to complete the construction works.
Leiden: A hub for innovation in cell therapy
Bristol Myers Squibb has chosen the Leiden Bio Science Park as the European site for its CAR-T cell therapy facility. This facility is a key part of our global expansion, which aims to bring novel cell therapies to patients with blood cancer across Europe and make it easier for them to access these personalised, life-changing treatments.
First European CAR-T production centre
The Leiden manufacturing centre is our first European site for CAR-T cell therapies, joining our global network of facilities transforming care for patients with blood cancer. Equipped with the latest technology and state-of-the-art production facilities, the centre represents our commitment to ensuring supply of CAR-T therapies.
It will play a central role in our efforts to meet the growing demand for CAR-T therapies in Europe, shortening lead times and improving patient outcomes by manufacturing them closer to patients' homes.
With this new production centre, we are contributing to the growing role of the Netherlands as an international leader in the field of CAR-T cell therapy.
What is CAR-T?
CAR-T stands for 'Chimeric Antigen Receptor T-cell' therapy. T-cells are immune cells that can attack and eliminate malignant cancer cells. White blood cells are taken from cancer patients who qualify for this therapy. These are genetically modified in our CAR-T cell therapy facility and then administered back to the patient in specialised centres. This treatment helps to fight hematological cancers via the body's own T-cells.
Leiden Bio Science Park
The Netherlands has everything that's needed to become the pharmaceutical hub of Europe, the 'Boston by the North Sea'.
Leiden Bio Science Park (LBSP) is the largest innovation district in the Netherlands in the field of Life Sciences & Health. The region offers a stimulating international community for innovation, cooperation and is a dynamic environment for life science professionals. In addition, transport connectivity is very important to us because of our work transporting patient cells. With the nearby airports of Schiphol and Rotterdam, Leiden is an ideal location.
The people who work,
live and reside at LBSP feel connected by one common mission: to
contribute to the development of new medicines and the improvement of
people's health through knowledge and innovation. LBSP also organises numerous events, workshops, sports and cultural activities.
Virtual BMS Cell Therapy Manufacturing Tour
.png)